Your session is about to expire
← Back to Search
RNAi
RXI-109 for Hypertrophic Scar
Phase 2
Waitlist Available
Research Sponsored by RXi Pharmaceuticals, Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights
Study Summary
The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic scar.
Eligible Conditions
- Hypertrophic Scar
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 9 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Reducing the recurrence of hypertrophic scar after scar revision surgery
Secondary outcome measures
Safety evaluation of RXI-109
Trial Design
1Treatment groups
Experimental Treatment
Group I: RXI-109Experimental Treatment1 Intervention
RXI-109 dosed at the site of the revised hypertrophic scar
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RXI-109
2012
Completed Phase 2
~80
Find a Location
Who is running the clinical trial?
RXi Pharmaceuticals, Corp.Lead Sponsor
6 Previous Clinical Trials
163 Total Patients Enrolled
Pamela Pavco, PhDStudy DirectorRXi Pharmaceuticals
3 Previous Clinical Trials
124 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What site did they apply to?
NCT02246465
What portion of applicants met pre-screening criteria?
Did not meet criteria
Share this study with friends
Copy Link
Messenger